



HAL
open science

Phenotypes Associated with Knockouts of Eight Dense Granule Gene Loci (GRA2-9) in Virulent *Toxoplasma gondii*.

Leah M Rommereim, Valeria Bellini, Barbara A Fox, Graciane Pètre, Camille Rak, Bastien Touquet, Delphine Aldebert, Jean-François Dubremetz, Marie-France Cesbron-Delauw, Corinne Mercier, et al.

► **To cite this version:**

Leah M Rommereim, Valeria Bellini, Barbara A Fox, Graciane Pètre, Camille Rak, et al.. Phenotypes Associated with Knockouts of Eight Dense Granule Gene Loci (GRA2-9) in Virulent *Toxoplasma gondii*. PLoS ONE, 2016, 11 (7), pp.e0159306. 10.1371/journal.pone.0159306 . hal-01539047

HAL Id: hal-01539047

<https://hal.science/hal-01539047>

Submitted on 26 May 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

RESEARCH ARTICLE

Phenotypes Associated with Knockouts of Eight Dense Granule Gene Loci (*GRA2-9*) in Virulent *Toxoplasma gondii*

Leah M. Rommereim^{1☯[‡]}, Valeria Bellini^{2,3☯[‡]}, Barbara A. Fox¹, Graciane Pètre^{2,3}, Camille Rak^{2,3}, Bastien Touquet^{2,3,4}, Delphine Aldebert^{2,3}, Jean-François Dubremetz^{5,6}, Marie-France Cesbron-Delauw^{2,3[‡]}, Corinne Mercier^{2,3[‡]}, David J. Bzik^{1*}

1 Department of Microbiology and Immunology, The Geisel School of Medicine at Dartmouth, Lebanon, NH, United States of America, **2** Laboratoire Adaptation et Pathogénie des Micro-organismes, Université Grenoble Alpes, Université Joseph Fourier, Grenoble, France, **3** Centre National de la Recherche Scientifique, Unité Mixte de Recherche 5163, Grenoble, France, **4** Station de Cytométrie en Images en Microbiologie (SCIMI platform), Grenoble, France, **5** Université Montpellier 2, Place Eugène Bataillon, Montpellier, France, **6** Centre National de la Recherche Scientifique, Unité Mixte de Recherche 5235, Montpellier, France

☯ These authors contributed equally to this work.

‡ Current address: Institute for Systems Biology, Seattle, WA, United States of America

‡ Current address: Laboratoire Techniques de l'Imagerie Médicale et de la Complexité Informatique, Mathématiques et Applications (TIMC-IMAG), CNRS UMR 5525, Université Grenoble Alpes, Grenoble, France

* David.J.Bzik@dartmouth.edu



OPEN ACCESS

Citation: Rommereim LM, Bellini V, Fox BA, Pètre S, Rak C, Touquet B, et al. (2016) Phenotypes Associated with Knockouts of Eight Dense Granule Gene Loci (*GRA2-9*) in Virulent *Toxoplasma gondii*. PLoS ONE 11(7): e0159306. doi:10.1371/journal.pone.0159306

Editor: Ira J Blader, University at Buffalo, UNITED STATES

Received: February 28, 2016

Accepted: June 30, 2016

Published: July 26, 2016

Copyright: © 2016 Rommereim et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information files.

Funding: The authors acknowledge the contribution of J. Surre and P. Girard (Bachelor internships). This work was supported by National Institutes of Health (NIH), USA, Grants AI108489, AI105563, AI104514, and AI097018 to David J. Bzik; Labex Parafrap (ANR-11-LABX-0024) and Fondation pour la Recherche Médicale to Marie-France Cesbron-Delauw; Cluster 10, Région Rhône-Alpes and ANR 11 EMMA 03201 to Corinne Mercier. Leah M. Rommereim was a trainee on NIH training grants

Abstract

Toxoplasma gondii actively invades host cells and establishes a parasitophorous vacuole (PV) that accumulates many proteins secreted by the dense granules (GRA proteins). To date, at least 23 GRA proteins have been reported, though the function(s) of most of these proteins still remains unknown. We targeted gene knockouts at ten *GRA* gene loci (*GRA1-10*) to investigate the cellular roles and essentiality of these classical GRA proteins during acute infection in the virulent type I RH strain. While eight of these genes (*GRA2-9*) were successfully knocked out, targeted knockouts at the *GRA1* and *GRA10* loci were not obtained, suggesting these GRA proteins may be essential. As expected, the $\Delta gra2$ and $\Delta gra6$ knockouts failed to form an intravacuolar network (IVN). Surprisingly, $\Delta gra7$ exhibited hyper-formation of the IVN in both normal and lipid-free growth conditions. No morphological alterations were identified in parasite or PV structures in the $\Delta gra3$, $\Delta gra4$, $\Delta gra5$, $\Delta gra8$, or $\Delta gra9$ knockouts. With the exception of the $\Delta gra3$ and $\Delta gra8$ knockouts, all of the GRA knockouts exhibited defects in their infection rate *in vitro*. While the single GRA knockouts did not exhibit reduced replication rates *in vitro*, replication rate defects were observed in three double *GRA* knockout strains ($\Delta gra4\Delta gra6$, $\Delta gra3\Delta gra5$ and $\Delta gra3\Delta gra7$). However, the virulence of single or double GRA knockout strains in CD1 mice was not affected. Collectively, our results suggest that while the eight individual GRA proteins investigated in this study (*GRA2-9*) are not essential, several GRA proteins may provide redundant and potentially important functions during acute infection.

5T32AI007363 and 2T32AI007519. Valeria Bellini was supported by a PhD fellowship from the Parafrap Labex. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

Introduction

Toxoplasma gondii is an obligate intracellular protozoan pathogen capable of infecting any living nucleated cell [1]. As one of the most successful protozoan parasites in the group of cyst-forming *Apicomplexa*, *Toxoplasma* is estimated to chronically infect at least a third of the world's population [2]. Infections in immune-competent individuals are typically asymptomatic, though toxoplasmosis can cause severe pathological effects in immune privileged areas such as the eye or developing fetus [3], and toxoplasmosis is life-threatening in immunocompromised patients [4].

Toxoplasma enters host cells via a rapid active invasion mechanism [5] and utilizes the host cell plasma membrane to form, within the host cytosol, a distinct compartment termed the parasitophorous vacuole (PV), in which it replicates and divides [6–8]. *Toxoplasma* invasion and PV formation require three *Apicomplexa*-specific organelles: the micronemes, rhoptries and dense granules. The secreted microneme proteins (MICs) [9] aid in adhesion to the host cell and, with the secreted rhoptry neck proteins (RONs) [10], in formation of a moving junction through which the motile parasite penetrates the host cell. The rhoptry organelles also release rhoptry bulb proteins (ROPs) into the host cell cytosol during invasion. Many ROP proteins re-localize to the non-fusogenic [11] PV membrane (PVM), while other ROP proteins remain in the host cytoplasm or gain access to the host cell nucleus where they contribute to reprogramming host gene expression [12].

Shortly after the formation of the PV, the dense granule proteins (GRAs) that are defined by their localization in electron dense granule organelles are massively secreted into the PV lumen [13–17]. A few proteins secreted by the dense granules exhibit homologies to proteins of known function such as cathepsin C [18], nucleoside triphosphate hydrolases (NTPases) [19, 20], an osteopontin-like protein [21], protease inhibitors [22, 23] and a lipolytic lecithin:cholesterol acyltransferase [24]. Yet, most GRA proteins do not have any identifiable gene homologues in species other than cyst-forming coccidians. Within the PV lumen, GRA2 initiates the formation of the membranous tubules that compose the intravacuolar network (IVN) and GRA6 stabilizes this network [25, 26], which is proposed to provide a scaffold for parasite replication [27, 28]. GRA7 aids in the formation of host organelle sequestering tubular structures (HOSTs), which are deep PVM invaginations that entrap single shortened host microtubules to direct host endocytic vacuoles to the PV for nutrient acquisition [29]. GRA7 also interacts with ROP2 and ROP4 [30] and acts in complex with ROP18 to bind host Immunity-related GTPase a6 (Irga6) [31], mediating resistance to a major interferon- γ (IFN- γ) triggered macrophage killing mechanism [32]. GRA22 was recently proposed to play a role in parasite egress [33]. GRA17 and GRA23 were identified as PVM-localized GRAs that mediate passive transport of small molecules [34]. Polymorphic type I GRA6 was recently shown to manipulate the host cell by activating the host transcription factor nuclear factor of activated T cells 4 (NFAT4) [35]. GRA5 increases the expression of CCR7 [36] and GRA25 induces the expression of CCL2 and C-X-C motif ligand 1 (CXCL1) [37]. Other GRA proteins are exported from the PV into the host cell cytosol and/or nucleus where they modify host cell signaling pathways [38]. This exported GRA protein class includes GRA15 [39], GRA16 [40], and GRA24 [41].

Genes encoding several GRA proteins identified in antigen-mapping studies have been previously deleted in virulent type I strains (GRA2, GRA5, GRA6, GRA7, GRA14 and GRA22) [25, 29, 31, 33, 42–44], or in low-virulence type II strains (GRA3, GRA4 and GRA6) [45, 46]. However, previous gene deletion studies in non- $\Delta ku80$ strains are complicated by frequent off-site mutation that could influence observed phenotypes [47].

In this study, we utilized the virulent type I $\Delta ku80$ strain that enables highly efficient and precise development of gene knockouts [46–48] or gene tagging [49] to target gene deletions at the

first ten *GRA* gene loci (*GRA1-10*). We isolated 8 of the 10-targeted knockouts ($\Delta gra2-9$) and investigated invasion, growth, morphology and virulence phenotypes. Overall, our findings validate phenotypes associated with several previously reported *GRA* knockouts, and suggest that while *GRA* proteins (*GRA2-9*) are individually not essential, several of these *GRA* proteins are likely to provide redundant and potentially crucial functions during acute infection.

Materials and Methods

Primers

All oligonucleotide primers used in the development of plasmids for targeting gene deletions (S1 Table) and primers used in the validation of targeted gene deletions (S2 Table) are shown in the supplementary material. Sequences for primer design and validation of targeting plasmids were obtained from ToxoDB [www.toxodb.org] [50].

Plasmid Construction

Plasmids were developed using yeast recombination cloning that fused a ~1-kb 5' target flank, a ~2-kb hypoxanthine-xanthine-guanine-phosphoribosyltransferase (*HXGPRT*) selectable marker cassette and a ~1-kb 3' target flank with pRS416 by homologous crossovers at recombination junctions [48]. DNA elements for yeast recombination were amplified from type I RH (EP; ATCC 40050) genomic DNA. All targeting plasmids were validated by restriction enzyme digests and by DNA sequencing. The sequenced and fully annotated type I GT1 strain [www.toxodb.org] was used to identify *GRA* gene loci and type I sequences for targeting plasmid assembly. Plasmid p Δ GRA1 was constructed by fusing the *HXGPRT* minigene cassette between a 1,095-bp 5' *GRA1* genomic target flank and a 940-bp 3' *GRA1* genomic target flank to delete nucleotides 5308191 to 5309090 of the *GRA1* locus on chromosome VIII annotated as TGGT1_270250. Plasmid p Δ GRA2 was constructed by fusing the *HXGPRT* minigene cassette between a 1,136-bp 5' *GRA2* genomic target flank and a 1,025-bp 3' *GRA2* genomic target flank to delete nucleotides 814572 to 812564 of the *GRA2* locus on chromosome X annotated as TGGT1_227620. Plasmid p Δ GRA2C was constructed by digesting p Δ GRA2 with *SpeI*, followed by self-ligation to remove the *HXGPRT* minigene cassette. Plasmid p Δ GRA3 was constructed by fusing the *HXGPRT* minigene cassette between a 950-bp 5' *GRA3* genomic target flank and a 860-bp 3' *GRA3* genomic target flank to delete nucleotides 988787 to 989625 of the *GRA3* locus on chromosome X annotated as TGGT1_227280. Plasmid p Δ GRA3C was constructed by digesting p Δ GRA3 with *SpeI*, followed by self-ligation to remove the *HXGPRT* minigene cassette. Plasmid p Δ GRA4 was constructed by fusing the *HXGPRT* minigene cassette between a 1,130-bp 5' *GRA4* genomic target flank and a 988-bp 3' *GRA4* genomic target flank to delete nucleotides 1201331 to 1200129 of the *GRA4* locus on chromosome XI annotated as TGGT1_310780. Plasmid p Δ GRA4C was constructed by digesting p Δ GRA4 with *SpeI*, followed by self-ligation to remove the *HXGPRT* minigene cassette. Plasmid p Δ GRA5 was constructed by fusing the *HXGPRT* minigene cassette between a 1,095-bp 5' *GRA5* genomic target flank and a 956-bp 3' *GRA5* genomic target flank to delete nucleotides 1753723 to 1754102 of the *GRA5* locus on chromosome V annotated as TGGT1_286450. Plasmid p Δ GRA6 was constructed by fusing the *HXGPRT* minigene cassette between a 1,057-bp 5' *GRA6* genomic target flank and a 975-bp 3' *GRA6* genomic target flank to delete nucleotides 7195269 to 7194367 of the *GRA6* locus on chromosome X annotated as TGGT1_275440. Plasmid p Δ GRA7 was constructed by fusing the *HXGPRT* minigene cassette between a 1,164-bp 5' *GRA7* genomic target flank and a 954-bp 3' *GRA7* genomic target flank to delete nucleotides 2582896 to 2585701 of the *GRA7* locus on chromosome VIIa, annotated as TGGT1_203310. Plasmid p Δ GRA8 was constructed by fusing the *HXGPRT* minigene cassette between a 1,151-bp 5' *GRA8* genomic target flank and a 1,015-bp 3' *GRA8* genomic target flank

to delete nucleotides 1894848 to 1895699 of the *GRA8* locus on chromosome III annotated as TGGT1_354720. Plasmid pΔGRA9 was constructed by fusing the *HXGPRT* minigene cassette between a 1,110-bp 5' *GRA9* genomic target flank and a 971-bp 3' *GRA9* genomic target flank to delete nucleotides 5508787 to 5510441 of the *GRA9* locus on chromosome XII annotated as TGGT1_251540. Plasmid pΔGRA10 was constructed by fusing the *HXGPRT* minigene cassette between a 1,170-bp 5' *GRA10* genomic target flank and a 967-bp 3' *GRA10* genomic target flank to delete nucleotide 6215048 to 6217010 of the *GRA10* locus on chromosome VIII annotated as TGGT1_268900.

Cell and Parasite Cultures

All parasites cultures were maintained *in vitro* by serial passages in human foreskin fibroblast (HFF) monolayers (ATCC SCRC-1041.1) in Eagle's modified essential medium (EMEM) supplemented with 1% fetal bovine serum (FBS) at 36°C [51]. As specified in the text, certain experiments were performed using Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS and 1% sodium pyruvate (D10 medium) or using lipid-free D10 medium (lfD10).

Gene Replacements and Deletions

All strains used or developed in this study are listed in Table 1. Parasites were transformed following previously described methods [47]. Gene replacements using the *HXGPRT* marker were selected in 25 µg/mL mycophenolic acid (MPA) and 50 µg/mL xanthine (MPA+X). *HXGPRT* deletion was selected using 200 µg/mL 6-thioxanthine (6TX). Genotype verification of precisely targeted gene replacement and deletion events was performed by PCR as previously described [47, 48].

Western Blots

Parasites were isolated from freshly lysed cultures and resuspended in Laemmli buffer. Proteins were separated by 13% SDS-PAGE (non-reduced conditions), transferred to nitrocellulose membranes and detected using the following primary antibodies: mAb TG17.179 anti-GRA2

Table 1. Strains used or developed in this study.

Strain	Parent Strain	Genotype
RHΔku80Δhxgprt [48]	RHΔku80::HXGPRT [48]	Δku80Δhxgprt
RHΔku80Δgra2::HXGPRT	RHΔku80Δhxgprt	Δku80Δgra2::HXGPRT
RHΔku80Δgra3::HXGPRT	RHΔku80Δhxgprt	Δku80Δgra3::HXGPRT
RHΔku80Δgra4::HXGPRT	RHΔku80Δhxgprt	Δku80Δgra4::HXGPRT
RHΔku80Δgra5::HXGPRT	RHΔku80Δhxgprt	Δku80Δgra5::HXGPRT
RHΔku80Δgra6::HXGPRT	RHΔku80Δhxgprt	Δku80Δgra6::HXGPRT
RHΔku80Δgra7::HXGPRT	RHΔku80Δhxgprt	Δku80Δgra7::HXGPRT
RHΔku80Δgra8::HXGPRT	RHΔku80Δhxgprt	Δku80Δgra8::HXGPRT
RHΔku80Δgra9::HXGPRT	RHΔku80Δhxgprt	Δku80Δgra9::HXGPRT
RHΔku80Δgra2Δhxgprt	RHΔku80Δgra2::HXGPRT	Δku80Δgra2Δhxgprt
RHΔku80Δgra3Δhxgprt	RHΔku80Δgra3::HXGPRT	Δku80Δgra3Δhxgprt
RHΔku80Δgra4Δhxgprt	RHΔku80Δgra4::HXGPRT	Δku80Δgra4Δhxgprt
RHΔku80Δgra2Δgra4::HXGPRT	RHΔku80Δgra2Δhxgprt	Δku80Δgra2Δgra4::HXGPRT
RHΔku80Δgra2Δgra6::HXGPRT	RHΔku80Δgra2Δhxgprt	Δku80Δgra2Δgra6::HXGPRT
RHΔku80Δgra4Δgra6::HXGPRT	RHΔku80Δgra4Δhxgprt	Δku80Δgra4Δgra6::HXGPRT
RHΔku80Δgra3Δgra5::HXGPRT	RHΔku80Δgra3Δhxgprt	Δku80Δgra3Δgra5::HXGPRT
RHΔku80Δgra3Δgra7::HXGPRT	RHΔku80Δgra3Δhxgprt	Δku80Δgra3Δgra7::HXGPRT

doi:10.1371/journal.pone.0159306.t001

(1:15,000) [16], mAb T6.2H11 anti-GRA3 (1:10,000) [52], rabbit anti-GRA4 (1:10,000) [53], mAb TG17.113 anti-GRA5 (1:5,000) [16], rabbit anti-GRA6 (1:20,000) [53], mAb BATO 214 anti-GRA7 (1:15,000) [54], mAb 3.2 anti-GRA8 (1:10,000) [55], rabbit anti-GRA9 (1:2,500) [56], rabbit anti-actin (1:10,000) [57] or mAb TG054 anti-SAG1 (1:15,000) [58] (antibodies purchased from the Biotem company, Apprieu, France or kindly provided by L. D. Sibley, Washington University School of Medicine, Saint-Louis, MO; D. Jacobs, Innogenetics-Fujirebio Europe N.V., Ghent, Belgium; G.E. Ward, University of Vermont College of Medicine, Burlington, VT; W. Daübener, Heinrich Heine Universität, Düsseldorf, Germany). Proteins were detected with horseradish peroxidase (HRP)-conjugated secondary antibodies (1:20,000; Jackson ImmunoResearch Laboratories) and the peroxidase activity was visualized by chemiluminescence using the Supersignal ECL system (Pierce Chemical).

Indirect immunofluorescence

Confluent HFFs were grown on glass coverslips and infected overnight with parasites. For experiments using lipid free medium, HFFs were equilibrated in lfd10 and parasites were passed three times in lfd10 prior to infection experiments. Infected cells were fixed in 5% formaldehyde, permeabilized with 0.002% saponin and blocked in 5% goat serum-5% FBS (in Phosphate Buffered Saline (PBS)). Cells were then incubated with primary antibodies for 1 hr in 1% FBS, 0.002% saponin. Primary antibodies used in this study included mAbTG17.179 anti-GRA2 (1:500), mAb T6.2H11 anti-GRA3 (1:500), rabbit anti-GRA4 (1:500), rabbit anti-GRA6 (1:500), mAb BATO 214 anti-GRA7 (1:500), mAb 3.2 anti-GRA8 (1:500), rabbit anti-GRA9 (1:500), and mAb TG 05.54 anti-SAG1 (1: 500). Infected cells were washed and incubated for 1 h with the following secondary antibodies: goat anti-mouse IgG (H+L)-Alexa 488 (1:500, Jackson) or goat anti-mouse IgG (H+L) Alexa 594 (1:500, Jackson) or goat anti-rabbit IgG (H+L) Alexa 488 (1:500, Jackson). Coverslips were then incubated with 5 µg/mL Hoechst 33342 for 10 min to stain nuclei, mounted in Mowiol and observed using a 100X objective on an Axioplan II microscope (Zeiss). Images were acquired using a Zeiss black and white camera and the Axio Vision software (release 4.7.1).

Transmission Electron Microscopy (TEM)

Monolayers of HFFs were grown to confluence on Permanox slides, infected for 24 h in D10- or in lfd10 medium, rinsed with PBS, fixed for 2 h with glutaraldehyde diluted in 0.2 M NaPO₄ pH 7.4 and processed for TEM, as previously described [25]. To allow preservation of the IVN, the infected cells were flat embedded and sectioned en face.

Intracellular Replication and Infectivity Assays

The intracellular growth rate was determined in HFFs in a 30-hr growth assay. Freshly lysed parasites were filtered through a Nuclepore filter to remove host cell debris and used to infect HFFs at a multiplicity of infection (MOI) of ~ 0.1. An hour after infection the monolayer was washed with PBS and fresh medium was added to the culture. Cultures were prepared in duplicate. At 30 h post-infection the number of parasites/vacuole was scored from 250 PVs per parasite strain to determine the average number of parasites per vacuole in an HFF cell with a single PV. Samples were represented as the average number of parasite(s) per PV (± SEM). Replication rates were compared between parental and knockout strains using a Student's *t*-test, with significance being represented as a *P* value <0.05.

For high throughput replication and infectivity assays, HFF cells were plated in 96 well plates (10,000 cells per well). Cells were grown for 48 h, rinsed with PBS and 40,000 parasites of each strain (MOI ~1–2) were deposited into the wells (250 µL per well). Plates were spun at

400 rpm for 1 min, then incubated for 2 h to allow parasite invasion. After 3 washes in PBS, fresh D10 medium was added to each well and the plates were returned to culture for 24 h. The infected monolayers were washed with PBS, incubated with 5 µg/mL Hoechst 33342 for 10 min, rinsed, saturated and permeabilized for 15 min with 5% goat serum– 0.1% triton-X100 (PBS-T), and incubated for 45 min with mAb TG17.043 anti-GRA1 (1:500, Biotem) in PBS-T. After washes, cells were incubated with goat anti-mouse IgG-Alexa 488 (1:500, Jackson), washed again, and analyzed by high content screening microscopy using an Olympus IX8 inverted microscope equipped with a black and white Orca ER Camera, and a LUCPLN 20xPH1 objective. Images of the entire surface of each well were analyzed using the ScanR software. The percentage of infected cells, the total number of parasites per PV as well as the percentage of PVs containing 1, 2, 4, 8, 16 parasites was determined for >5,000 PVs per strain. Statistical analyses were performed using a Student's *t*-test, with significance being represented as a *P*-value <0.05.

Ethics Statement

All animal experiments were performed in strict accordance with the U.S.A. Public Health Service Policy on Humane Care and Use of Laboratory Animals. Animals experiments were conducted in an AAALAC approved facility. All animal protocols (protocol bzik.dj2) were approved by the Institutional Animal Care and Use Committee (Dartmouth College: Animal Welfare Assurance Number #A3259-01). The humane endpoint of weight loss was used to determine when animals were euthanized ($\geq 17\%$ body weight loss). Animals were monitored daily until weight loss occurred then animals were monitored at least twice a day. If the humane endpoint was reached, animals were euthanized using CO₂ and additionally by cervical dislocation. All efforts, including providing diet gel recovery to mice with weight loss, were made to minimize suffering.

Acute infection

Adult female CD1 mice were obtained from Charles River Laboratory and mice were maintained in Techniplast Seal Safe mouse cages on vent racks and provided with enrichment materials at the Dartmouth-Hitchcock Medical Center (Lebanon, NH) mouse facility. Acute virulence was determined by a single intraperitoneal injection of the indicated numbers of tachyzoites into groups of four to eight week old female CD-1 mice (17–21g) per experiment. Studies were done in a blinded manner to minimize subjective bias. No unexpected deaths occurred during experiments. Survival was monitored for 30 days and the percentage of surviving animals was determined by the number of animals that survived / the total number of animals that were infected x 100. In all experiments, plaque forming units (PFUs) to tachyzoite ratios were determined at the time of parasite inoculation to verify infectivity of parasite preparations. Survival was analyzed by the Kaplan-Meier method and curves were compared using the log rank (Mantel-Cox) test in GraphPad Prism.

Results

Targeted deletion of GRA2, GRA3, GRA4, GRA5, GRA6, GRA7, GRA8, and GRA9 gene loci

To further investigate the role of the first 10 historically identified GRA proteins (*GRA1-10*), we precisely targeted knockouts at each of these unique *GRA* gene loci using the virulent type I genetic background deficient in nonhomologous end-joining [48]. Gene knockout targeting plasmids were constructed according to the representative pΔGRA targeting plasmid shown in

Fig 1A. These targeting plasmids position the *HXGPRT* selectable marker between the 5' and 3' DNA flanks of the *GRA* gene of interest, thereby replacing the *GRA* protein coding sequence with the *HXGPRT* selectable marker [59].




Fig 1. Construction and validation of the single *GRA*2-9 knockout strains. A) Strategy for disruption of a *GRA* gene locus by double crossover homologous recombination in type I *RHΔku80Δhxgprt* using a plasmid, *pΔGRA*, engineered to contain the 5' and 3' target flanks surrounding the *HXGPRT* selectable marker. Successful recombination events were selected by mycophenolic acid plus xanthine (MPA+X). This strategy is representative of each of the gene knockout attempts. B) Validation of the *Δgra4* targeted gene deletion by PCR. The control parental strain is positive for PCR 1 (~ 380 bp) and PCR 2 (~ 670 bp) but negative for PCR 3 (~ 1,100 bp) and PCR4 (~ 1,200 bp). Clones 1–12 exhibit the banding pattern of a targeted *Δgra4* gene knockout. M: DNA size ladder. C) Western blot validation of the deletion of *GRA*2-9. Cell lysates from the equivalent of 2×10^7 parasites were loaded per lane, separated on a 13% SDS-PAGE (non-reduced conditions), probed with primary antibodies (indicated on the side of the gels), then with goat anti-mouse IgG or goat anti-rabbit IgG, both coupled to peroxidase and visualized by chemiluminescence.

doi:10.1371/journal.pone.0159306.g001

Following transfection into the RH $\Delta ku80\Delta hxp rt$ parental strain [48] and MPA+X selection, we isolated knockout strains deleted for *GRA2* ($\Delta gra2$), *GRA3* ($\Delta gra3$), *GRA4* ($\Delta gra4$), *GRA5* ($\Delta gra5$), *GRA6* ($\Delta gra6$), *GRA7* ($\Delta gra7$), *GRA8* ($\Delta gra8$), and *GRA9* ($\Delta gra9$). Knockouts at the *GRA1* and *GRA10* loci were not obtained despite repeated transfection-selection attempts. The genotypes of the $\Delta gra2-9$ knockout strains (Table 1) were validated by PCR as shown in Fig 1B for the $\Delta gra4$ strain. The deletion of each GRA protein was also confirmed by western blot (Fig 1C), and also by indirect immunofluorescence in HFFs infected overnight (Fig 2).

The loss of single GRA genes does not affect the replication rate

GRA proteins have been proposed to facilitate interactions with the host cell and to potentially mediate nutrient acquisition [60]. We used two different methodologies to investigate whether GRA2-9 are necessary for parasite growth *in vitro*. First, we infected HFFs with each of the knockout strains and monitored the parasite replication rate by directly counting the number of parasites per PV in 250 PVs at 30 h post-infection by light microscopy. Using this direct method, we did not observe any significant defect in replication rates determined by scoring the number of parasites per PV (Table 2).

To extend this analysis and potentially detect subtle growth defects by analyzing a larger sample size of more than 5,000 PVs, we used a high throughput automated immunofluorescence method to quantify the percentage of PVs containing 1, 2, 4, 8, 16 parasites and determine the average number of parasites per vacuole (replication rate), as well as the number of infected HFF cells (infection rate). The results confirmed the data shown in Table 2 revealing there was no significant reduction in the replication rate of single GRA knockout strains (Fig 3A), though the $\Delta gra7$ knockout did exhibit a slight increase in the percentage of PVs containing only 1 or 2 parasites. In contrast, a significant decrease in the infection rate was observed for the $\Delta gra2$, $\Delta gra4$, $\Delta gra5$, $\Delta gra6$, $\Delta gra7$, and $\Delta gra9$ knockout strains (Fig 3B).

Alteration of the intravacuolar network after deletion of GRA2, GRA6 and GRA7

To test whether the absence of lipids in growth medium would reveal any distinct morphologic changes in the $\Delta gra2-9$ knockout strains, we infected HFFs in normal D10 medium or HFFs that were pre-equilibrated in lfd10 medium. Each of the *GRA* knockout strains developed normal appearing PVs in both D10 (Fig 2) and in lfd10 media as assessed by indirect immunofluorescence assays (Fig 4).

Therefore, we assessed the morphology of the parental and *GRA* knockout strains cultured *in vitro* in D10 or lfd10 media by transmission electron microscopy (TEM). In the $\Delta gra2$ (Fig 5A) and $\Delta gra6$ (data not shown) knockout strains the parasites, their dense granules and PVM appeared normal; however, no IVN was observed in mature PVs grown in normal D10 medium (Fig 5A and data not shown), confirming previously reported phenotypes [25]. The absence of IVN in the mature PV of $\Delta gra2$ and $\Delta gra6$ strains was also observed in lfd10 medium (Fig 5A and data not shown). Interestingly, the $\Delta gra7$ knockout exhibited an increase in the density of membranous tubules and vesicles that form the IVN of parasites grown both in D10 and lfd10 media (Fig 5A and 5B). No major morphologic changes in the parasites or their PV were observed in other *GRA* knockout strains cultured in normal D10 or delipidated lfd10 conditions (Fig 5 and data not shown).

Targeted double deletions of dense granule genes

We generated several double *GRA* knockout strains for GRA proteins that were previously reported to associate or co-localize [61] to assess whether these GRA proteins may provide

D




Fig 2. Indirect immunofluorescence assay verifies deletion of GRA proteins. IFA validation of the deletion of GRA2-9. HFFs were infected overnight with Δgra knockout strains or with the parental strain. Infected cells were fixed, permeabilized with 0.002% saponin and incubated with the appropriate primary antibodies (see [Material and Methods](#)), followed by Alexa 488-coupled goat anti-mouse IgG or goat anti-rabbit IgG secondary antibodies. After labeling both the host- and parasite nuclei were revealed with Hoechst 33342; coverslips were mounted in Mowiol and observed by epifluorescence. To distinguish the shape of Δgra mutants' vacuoles in the absence of fluorescent signal, we chose to artificially increase their exposure time, which may lead to some artificial background noise. Scales: 5 μ m.

doi:10.1371/journal.pone.0159306.g002

redundant functions. The *HXGPRT* marker present in the disrupted *GRA* locus was excised using the *pΔGRAc* plasmid and selection in 6-thioxanthine to generate the corresponding $\Delta gra\Delta hxgpRT$ strain ([Fig 6A](#)), and genotypes were validated by PCR ([Fig 6B](#)). The $\Delta gra\Delta hxgpRT$

Table 2. Intracellular replication rate of single *Δgra* knockout parasite strains.

Strain	Mean number of parasites per vacuole ^a (±SEM)	<i>P</i> (compared to the control strain) ^b	
		Significance	Control strain genotype
RHΔ <i>ku80</i> ::HXGPRT [48]	19.85 ± 0.76		
RHΔ <i>ku80Δgra2</i> ::HXGPRT	19.06 ± 1.29	NS	RHΔ <i>ku80</i> ::HXGPRT
RHΔ <i>ku80Δgra3</i> ::HXGPRT	17.12 ± 1.81	NS	RHΔ <i>ku80</i> ::HXGPRT
RHΔ <i>ku80Δgra4</i> ::HXGPRT	18.94 ± 1.63	NS	RHΔ <i>ku80</i> ::HXGPRT
RHΔ <i>ku80Δgra5</i> ::HXGPRT	22.44 ± 0.83	NS	RHΔ <i>ku80</i> ::HXGPRT
RHΔ <i>ku80Δgra6</i> ::HXGPRT	20.82 ± 0.12	NS	RHΔ <i>ku80</i> ::HXGPRT
RHΔ <i>ku80Δgra7</i> ::HXGPRT	23.38 ± 0.34	NS	RHΔ <i>ku80</i> ::HXGPRT
RHΔ <i>ku80Δgra8</i> ::HXGPRT	19.72 ± 2.23	NS	RHΔ <i>ku80</i> ::HXGPRT
RHΔ <i>ku80Δgra9</i> ::HXGPRT	21.60 ± 1.78	NS	RHΔ <i>ku80</i> ::HXGPRT

^a The number of parasites per vacuole was scored at 30 h PI in HFF cells containing a single PV.

^b *P* value was determined by a Student's *t*-test. NS, not significant at *P* ≤ 0.05.

doi:10.1371/journal.pone.0159306.t002

knockout strains were then used to generate double *GRA* knockout strains following the forward strategy illustrated in Fig 1A using MPA + X selection. Five double *GRA* knockout mutants were generated: *Δgra2Δgra4*, *Δgra2Δgra6*, *Δgra4Δgra6*, *Δgra3Δgra5* and *Δgra3Δgra7* (Table 1). Interestingly, despite several attempts, we failed to isolate a *Δgra2Δgra4Δgra6* triple knockout strain even though each of the three corresponding double *GRA* knockout gene combinations was successfully isolated (Table 1).

Double *GRA* knockout strains display defects in replication rate

We measured the *in vitro* replication rates of the double *GRA* knockout strains via direct counting of parasites in > 250 PVs 30 h post-infection. The *Δgra4Δgra6*, *Δgra3Δgra5* and *Δgra3Δgra7* knockout strains exhibited mild defects in their *in vitro* replication rate (Table 3). No growth replication defects were observed for the *Δgra2Δgra4* or *Δgra2Δgra6* knockout strains (Table 3).

Deletion of *GRA2-9* does not affect acute infection or virulence *in vivo*

Previous work identified several *GRA* proteins (*GRA2*, *GRA6*, and *GRA7*) as playing a role in type I parasite virulence during acute infection [25, 31, 37, 42]. To examine the virulence of the *Δgra2-9* knockout strains, we infected CD-1 female mice intraperitoneally with 100 tachyzoites (parental RH strain LD₁₀₀ = 1 parasite) and monitored their survival. Absence of these individual *GRA* proteins (Fig 7A and 7B) or multiple *GRA* proteins (Fig 7C) did not increase or decrease virulence during acute infection. All mice succumbed to the infection within 8–12 days.

Discussion

The aim of this study was to apply a more systematic and reliable genetic approach using the virulent type I strain *Δku80* genetic background to examine or re-examine phenotypes associated with the absence of the dense granule proteins *GRA1-10*. Previously, only one of these ten *GRA* proteins (*GRA7*, [31]) was knocked out in a background that eliminates off-target mutations that could influence phenotypes in non-*Δku80* strains [47]. Using the virulent type I *Δku80* genetic model that enables efficient and precise targeted deletion [46–48], we successfully generated parasite strains containing single and double deletions of the *GRA* loci *GRA2-9*




Fig 3. Replication and infection rates of single $\Delta gra2-9$ gene knockout strains calculated by high throughput microscopy. A) Replication rate of each of the $\Delta gra2-9$ strains compared to that of the parental strain. The percentage of PVs containing 1, 2, 4, 8 or 16 parasites per vacuole was calculated from three coverslips of infected HFFs. The numbers above each bar represent the average number of parasites per vacuole calculated from the total number obtained the three coverslips. The values are representative of one experiment out of three, which provided similar results. B) Percentage of HFFs infected by each $\Delta gra2-9$ knockout strain versus the parental $\Delta ku80$ strain. The infection rate was calculated from the number of PVs observed on three coverslips. Comparisons between the parental strain and each of the knockout strains were performed using a Student's *t*-test and asterisks indicate significant differences. *: $p = 0.0128$ for $\Delta gra9$; **: $p = 0.0099$ for $\Delta gra2$, 0.0022 for $\Delta gra4$, 0.0051 for $\Delta gra7$; ***: $p = 0.0003$ for $\Delta gra5$ and 0.0007 for $\Delta gra6$. The values are representative of one experiment out of three, which provided similar results. The total number of PVs observed in A and B are respectively: parental $\Delta ku80$ strain, 5,757 (left panel) and 5,206 (right panel); $\Delta gra2$, 5,200; $\Delta gra3$, 5,173; $\Delta gra4$, 6,176; $\Delta gra5$, 5,845; $\Delta gra6$, 6,311; $\Delta gra7$, 5,165; $\Delta gra8$, 5,177; $\Delta gra9$, 5,065.

doi:10.1371/journal.pone.0159306.g003




Fig 4. PV formation by Δ gra2-9 single knockout strains in normal and lipid-free media. HFFs were pre-equilibrated in lipid-free D10 media (lfD10), then infected overnight with a single Δ gra knockout parasite strain or the Δ ku80 parental strain. All parasite strains were passaged 3 times in lfD10 medium prior to infecting HFFs. Infected cells were fixed, permeabilized with 0.002% saponin, incubated with rabbit serum anti-GRA6 (all strains but Δ gra6) or with rabbit serum anti-GRA4 (Δ gra6) and with mAb anti-SAG1, visualized with goat anti-rabbit IgG coupled to Alexa 488 and goat anti-mouse IgG coupled to Alexa 594, mounted in Mowiol and observed by epifluorescence. To distinguish the shape of Δ gra mutants' vacuoles in the absence of fluorescent signal, we chose to artificially increase their exposure time, which may lead to some background noise. Scales: 5 μ m.

doi:10.1371/journal.pone.0159306.g004




Fig 5. Visualization of the $\Delta gra2-9$ knockout parasites and PV morphology by transmission electron microscopy. A) HFFs and parasites were cultured in D10 medium (“Normal D10”) or pre-equilibrated in lipid-free D10 medium (“Lipid-free D10”). Host cells were infected overnight with $\Delta gra2-9$ knockout or parental strains, fixed, and then processed for transmission electron microscopy. Scale: 2 μm . B) Magnification of the posterior end of an intracellular $\Delta gra7$ knockout parasite in “Normal D10” and in “Lipid-free D10” showing the hyper-formation of the IVN. Scales: 2 μm .

doi:10.1371/journal.pone.0159306.g005

(Table 1). This study is the first to report results on knockouts at the *GRA3*, *GRA4*, *GRA8* and *GRA9* loci, as well as results on the double *GRA* knockouts $\Delta gra2\Delta gra4$, $\Delta gra4\Delta gra6$, $gra3\Delta gra5$ and $\Delta gra3\Delta gra7$ in the virulent type I RH genetic background.

While knockouts were readily isolated at the *GRA2-9* loci, we could not isolate a *Δgra1* or a *Δgra10* knockout, suggesting the possibility that these *GRA* genes are required for parasite growth or survival, though additional experiments would be necessary to validate this conclusion. Previously, RNA-knockdown of *GRA10* expression severely inhibited growth of the parasite *in vitro* [62]. *GRA1* encodes a *GRA* protein that localizes to the PV lumen as a calcium-binding [63], soluble protein [13]. This unique localization and the inability to knockout these genes in a type I strain suggests that *GRA1* and *GRA10* may participate in essential growth functions. The potential essentiality of the *GRA1* and *GRA10* genes could be further addressed in the future using either an inducible type I deletion scheme such as Cre-recombinase [64], an




Fig 6. Strategy for removal of the HXGPRT selectable marker from a GRA gene locus. A) Removal of the HXGPRT selectable marker from RHΔku80Δgra::HXGPRT. This strategy is representative of each of the HXGPRT removal attempts. Following transfection with an HXGPRT-excised plasmid, clones lacking HXGPRT but containing the 5' and 3' flanking regions of the original GRA locus were generated by double-crossover homologous recombination, using 6TX selection. B) Validation of the HXGPRT removal from the gra4 gene locus. The parental strain exhibits a PCR5 amplicon of ~ 2,300 bp, corresponding to a DNA fragment that includes the HXGPRT coding sequence. Clones 1–12 exhibit a PCR5 amplicon of ~ 1,100 bp, which corresponds to the removal of HXGPRT. M: DNA size ladder; C: control parental strain.

doi:10.1371/journal.pone.0159306.g006

inducible type I expression scheme [65], the CRISPR (clustered regularly interspaced short palindromic repeats)/CAS9 technology [66], or alternatively to apply the recently developed type II Δku80 genetic model [46] which exhibits extremely rare or undetectable off-site targeting in comparison to type I Δku80 genetic models [47].

Table 3. Intracellular replication rate of double Δgra knockout parasite strains.

Strain	Mean number of parasites per vacuole ^a (±SEM)	P (compared to the control strain) ^b	
		Significance	Control strain genotype
RHΔku80::HXGPRT (48)	19.85 ± 0.76		
RHΔku80Δgra2Δgra4::HXGPRT	16.89 ± 1.12	NS	RHΔku80::HXGPRT
RHΔku80Δgra2Δgra6::HXGPRT	18.97 ± 0.56	NS	RHΔku80::HXGPRT
RHΔku80Δgra4Δgra6::HXGPRT	15.53 ± 0.68	S	RHΔku80::HXGPRT
RHΔku80Δgra3Δgra5::HXGPRT	14.14 ± 0.75	S	RHΔku80::HXGPRT
RHΔku80Δgra3Δgra7::HXGPRT	14.85 ± 0.60	S	RHΔku80::HXGPRT

^a The number of parasites per vacuole was scored at 30 h post-infection in HFF cells containing a single PV.

^b P value was determined by a Student's T-test. S, significant at P ≤ 0.05; NS, not significant.

doi:10.1371/journal.pone.0159306.t003




Fig 7. Virulence of single and double GRA knockout strains in CD1 mice. One hundred tachyzoites of the parental ($\Delta ku80$) or knockout (Δgra) strains were injected intraperitoneally (i.p.) into 8 week old female CD1 mice and survival was followed for 30 days ($n = 8$ for $\Delta gra3$, $\Delta gra4$, $\Delta gra7$, $\Delta gra9$, $\Delta gra3\Delta gra5$ and $\Delta gra3\Delta gra7$, $n = 4$ for $\Delta gra2$, $\Delta gra5$, $\Delta gra6$, $\Delta gra8$, $\Delta gra2\Delta gra4$, $\Delta gra2\Delta gra6$, and $\Delta gra4\Delta gra6$). A) Survival of mice infected with parasites containing single GRA knockouts for IVN-localized GRA proteins. B) Survival of mice infected with parasites containing single GRA knockouts for PVM-localized GRA proteins. C) Survival of mice infected with parasites containing double GRA knockouts. Significance was determined by a Student's t-test comparing the knockout strain with the parental.

doi:10.1371/journal.pone.0159306.g007

Each of the GRA2-9 proteins contains either a transmembrane hydrophobic alpha-helix or amphipathic alpha-helices [67] that allow for insertion into and localization at the PVM and/or the IVN membranes. In addition, GRA2 and GRA6 induce formation and maturation of the IVN [25, 26] GRA7 was previously identified as a GRA protein possessing the ability to tubulate membranes *in vitro* [29]. We examined the parasite and PV morphologies of single GRA knockout strains cultured in both normal D10- and lipid free lfd10 media by indirect

immunofluorescence and TEM. Interestingly, any phenotype observed in the D10 medium was also present in the delipidated lfd10 medium. For all single *GRA* knockout strains the parasites, their dense granules and their PVM appeared normal in D10 as well as in lfd10 medium. Any morphological differences in the knockouts occurred only in the IVN structures, reinforcing the importance of certain *GRA* proteins as key regulators of the formation and maintenance of the IVN. In corroboration with previous reports [25], the $\Delta gra2$ and the $\Delta gra6$ knockout strains lacked an IVN in D10 and in delipidated lfd10 media. In contrast, the $\Delta gra7$ knockout strain exhibited a hyper-formation of the IVN in both D10 and lfd10 media. TEM images of a previously reported $\Delta gra7$ knockout strain [31] also suggests the possibility of hyper-formation of the IVN, although additional studies are necessary to conclusively determine the magnitude and significance of this phenotype. While *GRA2* and *GRA6* are associated with the IVN membranes, *GRA7* associates with the PVM but not directly with the IVN membranes [68]. *GRA7* was previously shown to deform liposomes into tubular membranes [29], as well as interact with *GRA2* and *GRA6* [61]. Collectively, these observations suggest that *GRA7* may coordinately regulate IVN functions in conjunction with *GRA2* and *GRA6*. The IVN membranes were also recently implicated in heterophagy since deletion of *GRA2* and subsequent loss of the IVN decreased the rate at which parasites ingest host cytosolic proteins [69]. The complex relationship of *GRA* protein functions in the context of PV membrane functions and IVN membrane functions merits further investigation.

The high throughput growth assay revealed significant defects in the infection rate in the $\Delta gra2$, $\Delta gra4$, $\Delta gra5$, $\Delta gra6$, $\Delta gra7$, and $\Delta gra9$ knockout strains. However, with the exception of a slight increase in percentage of $\Delta gra7$ parasite vacuoles with only 1 or 2 parasites, we did not detect any significant replication rate defect in any of the single *GRA* knockout strains by direct scoring of PVs or by automated high-throughput microscopy. *GRA* proteins traffic as soluble protein complexes with other *GRA* proteins to the IVN and PVM [61]. Once inserted into the membranes they can interact with similarly localized *GRA* [61] and *ROP* proteins [30, 31]. Therefore, to determine if *GRA* proteins could play redundant roles, we generated double *GRA* knockout strains of *GRA* proteins reported to reside in *GRA* complexes or of *GRA* proteins which share similar localization: $\Delta gra2\Delta gra4$, $\Delta gra2\Delta gra6$, $\Delta gra4\Delta gra6$, $\Delta gra3\Delta gra5$ and $\Delta gra3\Delta gra7$. Of these double *GRA* knockout strains, we found that the $\Delta gra4\Delta gra6$, $\Delta gra3\Delta gra5$ and $\Delta gra3\Delta gra7$ knockouts displayed significant replication defects *in vitro*, though the corresponding single knockouts did not. These results suggest that certain *GRA* proteins most likely serve redundant function(s) during the tachyzoite stage, or potentially function in a similar pathway.

Though the canonical *GRA* proteins are heavily expressed during tachyzoite stages [70], they appear to be dispensable for acute virulence in type I strains. None of the single or double deletion strains that we tested exhibited any significant defects in virulence following intraperitoneal infection of CD-1 mice. In contrast, several type I *GRA* knockout strains were previously reported to exhibit detectable defects in acute virulence: $\Delta gra2$ [42], $\Delta gra6$ [25, 37], and $\Delta gra7$ [31]. In our virulence assays we injected mice with a dose of 100 tachyzoites using the intraperitoneal route. Previously, Mercier *et al.* injected many mice with 10 parasites to detect a minor defect in $\Delta gra2$ virulence [42]. In addition, the decreased virulence phenotype of type I $\Delta gra6$ and $\Delta gra7$ mutants was previously observed following the infection of mice at atypical sites (sub-cutaneously or in the footpad) [31, 37].

Based on their pattern of secretion and their localization at the PVM as well as at the IVN, the *GRA2-9* proteins may play a role in host-pathogen interactions, nutrient acquisition or vacuole integrity. While we could isolate double *GRA* knockouts of any double combination of $\Delta gra2$, $\Delta gra4$, and $\Delta gra6$, we could not isolate the triple *GRA* knockout— $\Delta gra2\Delta gra4\Delta gra6$. Collectively, our results suggest that while *GRA2-9* individually provide non-essential

functions for acute infection, some of these GRA proteins in complexes are likely to play redundant but necessary roles during acute infection. Additional experiments are still necessary to further define these functions.

The *GRA2-9* genes characterized in this study may play essential roles during transition to or growth in other life stages such as the development of tissue cysts that establish chronic infection. Most of the *GRA2-9* proteins are expressed not only at the tachyzoite stage but also in the encysted bradyzoite stage [71–74]. Furthermore, a significant role for several of these GRA proteins (*GRA3*, *GRA4*, and *GRA6*) in type II strains has been reported [45, 46]. These findings suggest that a key role of PVM- and IVN-localized GRAs may be to prepare the PV for cyst formation or to provide essential functions during the encysted tissue stages [68]. Though the function of a large number of GRA proteins remains elusive, our study 1) has reported for the first time the *GRA3*, *GRA4*, *GRA8* and *GRA9* knockouts as well as double knockouts for *GRA2-9* in the type I RH background and 2) has determined that *GRA2-9* are not required for acute virulence following intraperitoneal infection of mice. Additionally we have identified that a subset of GRA proteins, which cooperate in complexes, appear to provide key functions associated with IVN formation or function.

Supporting Information

S1 Table. Primers used for generating Δgra knockout strains.

(DOC)

S2 Table. Primers used for validating Δgra knockout strains.

(DOC)

Acknowledgments

The authors acknowledge the following persons for sharing antibodies: L. D. Sibley, Washington University School of Medicine, Saint-Louis, MO; G.E. Ward, University of Vermont College of Medicine, Burlington, VT; W. Daübener, Heinrich Heine Universität, Düsseldorf, Germany; and D. Jacobs, Innogenetics-Fujirebio Europe N.V., Ghent, Belgium. They acknowledge the contribution of J. Surre and P. Girard (Bachelor internships). This work was supported by National Institutes of Health (NIH), USA, Grants AI108489, AI105563, AI104514, and AI097018 to D.J.B.; Labex Parafrap (ANR-11-LABX-0024) and Fondation pour la Recherche Médicale to M.F.C.D.; Cluster 10, Région Rhône-Alpes and ANR 11 EMMA 03201 to C. M. L.M.R. was a trainee on NIH training grants 5T32AI007363 and 2T32AI007519. V.B. was supported by a PhD fellowship from the Parafrap Labex.

Author Contributions

Conceived and designed the experiments: LMR BAF DJB CM. Performed the experiments: LMR BAF VB GP CR BT DA. Analyzed the data: LMR BAF VB JFD MFCD CM DJB. Wrote the paper: LMR VB BAF CM MFCD DJB.

References

1. Dubey JP. Advances in the life cycle of *Toxoplasma gondii*. International journal for parasitology. 1998; 28(7):1019–24. Epub 1998/09/02. PMID: [9724872](#).
2. Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet. 2004; 363(9425):1965–76. Epub 2004/06/15. doi: [10.1016/S0140-6736\(04\)16412-X](#) PMID: [15194258](#).
3. Montoya JG, Remington JS. Management of *Toxoplasma gondii* infection during pregnancy. Clin Infect Dis. 2008; 47(4):554–66. PMID: [18624630](#) doi: [10.1086/590149](#)

4. Hill DE, Chirukandoth S, Dubey JP. Biology and epidemiology of *Toxoplasma gondii* in man and animals. *Anim Health Res Rev*. 2005; 6(1):41–61. PMID: [16164008](#).
5. Carruthers V, Boothroyd JC. Pulling together: an integrated model of *Toxoplasma* cell invasion. *Current opinion in microbiology*. 2007; 10(1):83–9. Epub 2006/07/14. doi: [10.1016/j.mib.2006.06.017](#) PMID: [16837236](#).
6. Hakansson S, Charron AJ, Sibley LD. *Toxoplasma* evacuoles: a two-step process of secretion and fusion forms the parasitophorous vacuole. *The EMBO journal*. 2001; 20(12):3132–44. Epub 2001/06/19. doi: [10.1093/emboj/20.12.3132](#) PMID: [11406590](#); PubMed Central PMCID: PMC150190.
7. Charron AJ, Sibley LD. Host cells: mobilizable lipid resources for the intracellular parasite *Toxoplasma gondii*. *Journal of cell science*. 2002; 115(Pt 15):3049–59. Epub 2002/07/16. PMID: [12118061](#).
8. Charron AJ, Sibley LD. Molecular partitioning during host cell penetration by *Toxoplasma gondii*. *Traffic*. 2004; 5(11):855–67. Epub 2004/10/14. doi: [10.1111/j.1600-0854.2004.00228.x](#) PMID: [15479451](#).
9. Carruthers VB, Tomley FM. Microneme proteins in apicomplexans. *Sub-cellular biochemistry*. 2008; 47:33–45. Epub 2008/06/03. PMID: [18512339](#); PubMed Central PMCID: PMC2847500.
10. Besteiro S, Dubremetz JF, Lebrun M. The moving junction of apicomplexan parasites: a key structure for invasion. *Cellular microbiology*. 2011; 13(6):797–805. Epub 2011/05/04. doi: [10.1111/j.1462-5822.2011.01597.x](#) PMID: [21535344](#).
11. Mordue DG, Hakansson S, Niesman I, Sibley LD. *Toxoplasma gondii* resides in a vacuole that avoids fusion with host cell endocytic and exocytic vesicular trafficking pathways. *Experimental parasitology*. 1999; 92(2):87–99. Epub 1999/06/15. PMID: [10366534](#).
12. Boothroyd JC, Dubremetz JF. Kiss and spit: the dual roles of *Toxoplasma* rhoptries. *Nat Rev Microbiol*. 2008; 6(1):79–88. PMID: [18059289](#).
13. Sibley LD, Niesman IR, Parmley SF, Cesbron-Delauw MF. Regulated secretion of multi-lamellar vesicles leads to formation of a tubulo-vesicular network in host-cell vacuoles occupied by *Toxoplasma gondii*. *J Cell Sci*. 1995; 108 (Pt 4):1669–77. PMID: [7615684](#).
14. Carruthers VB, Sibley LD. Sequential protein secretion from three distinct organelles of *Toxoplasma gondii* accompanies invasion of human fibroblasts. *Eur J Cell Biol*. 1997; 73(2):114–23. PMID: [9208224](#).
15. Dubremetz JF, Achbarou A, Bermudes D, Joiner KA. Kinetics and pattern of organelle exocytosis during *Toxoplasma gondii*/host-cell interaction. *Parasitology research*. 1993; 79(5):402–8. Epub 1993/01/01. PMID: [8415546](#).
16. Charif H, Darcy F, Torpier G, Cesbron-Delauw MF, Capron A. *Toxoplasma gondii*: characterization and localization of antigens secreted from tachyzoites. *Experimental parasitology*. 1990; 71(1):114–24. Epub 1990/07/01. PMID: [2191870](#).
17. Mercier C, Adjogble KD, Daubener W, Delauw MF. Dense granules: are they key organelles to help understand the parasitophorous vacuole of all apicomplexa parasites? *International journal for parasitology*. 2005; 35(8):829–49. Epub 2005/06/28. doi: [10.1016/j.ijpara.2005.03.011](#) PMID: [15978597](#).
18. Que X, Engel JC, Ferguson D, Wunderlich A, Tomavo S, Reed SL. Cathepsin Cs are key for the intracellular survival of the protozoan parasite, *Toxoplasma gondii*. *The Journal of biological chemistry*. 2007; 282(7):4994–5003. Epub 2006/12/14. doi: [10.1074/jbc.M606764200](#) PMID: [17164247](#).
19. Bermudes D, Peck KR, Afifi MA, Beckers CJ, Joiner KA. Tandemly repeated genes encode nucleoside triphosphate hydrolase isoforms secreted into the parasitophorous vacuole of *Toxoplasma gondii*. *J Biol Chem*. 1994; 269(46):29252–60. PMID: [7961894](#).
20. Asai T, Miura S, Sibley LD, Okabayashi H, Takeuchi T. Biochemical and molecular characterization of nucleoside triphosphate hydrolase isozymes from the parasitic protozoan *Toxoplasma gondii*. *J Biol Chem*. 1995; 270(19):11391–7. PMID: [7744775](#).
21. Cortez E, Stumbo AC, Saldanha-Gama R, Villela CG, Barja-Fidalgo C, Rodrigues CA, et al. Immunolocalization of an osteopontin-like protein in dense granules of *Toxoplasma gondii* tachyzoites and its association with the parasitophorous vacuole. *Micron*. 2008; 39(1):25–31. Epub 2007/10/13. doi: [10.1016/j.micron.2007.08.007](#) PMID: [17931871](#).
22. Pszenny V, Ledesma BE, Matrajt M, Duschak VG, Bontempi EJ, Dubremetz JF, et al. Subcellular localization and post-secretory targeting of TgPI, a serine proteinase inhibitor from *Toxoplasma gondii*. *Molecular and biochemical parasitology*. 2002; 121(2):283–6. Epub 2002/05/30. PMID: [12034464](#).
23. Morris MT, Coppin A, Tomavo S, Carruthers VB. Functional analysis of *Toxoplasma gondii* protease inhibitor 1. *The Journal of biological chemistry*. 2002; 277(47):45259–66. Epub 2002/09/14. doi: [10.1074/jbc.M205517200](#) PMID: [12228242](#).
24. Pszenny V, Ehrenman K, Romano JD, Kennard A, Schultz A, Roos DS, et al. A Lipolytic Lecithin:Cholesterol Acyltransferase Secreted by *Toxoplasma* Facilitates Parasite Replication and Egress. *The*

- Journal of biological chemistry. 2016; 291(8):3725–46. Epub 2015/12/24. doi: [10.1074/jbc.M115.671974](https://doi.org/10.1074/jbc.M115.671974) PMID: [26694607](https://pubmed.ncbi.nlm.nih.gov/26694607/); PubMed Central PMCID: PMC4759155.
25. Mercier C, Dubremetz JF, Rauscher B, Lecordier L, Sibley LD, Cesbron-Delauw MF. Biogenesis of nanotubular network in *Toxoplasma* parasitophorous vacuole induced by parasite proteins. *Molecular biology of the cell*. 2002; 13(7):2397–409. Epub 2002/07/23. doi: [10.1091/mbc.E02-01-0021](https://doi.org/10.1091/mbc.E02-01-0021) PMID: [12134078](https://pubmed.ncbi.nlm.nih.gov/12134078/); PubMed Central PMCID: PMC117322.
 26. Lopez J, Bittame A, Massera C, Vasseur V, Effantin G, Valat A, et al. Intravacuolar Membranes Regulate CD8 T Cell Recognition of Membrane-Bound *Toxoplasma gondii* Protective Antigen. *Cell reports*. 2015; 13(10):2273–86. Epub 2015/12/03. doi: [10.1016/j.celrep.2015.11.001](https://doi.org/10.1016/j.celrep.2015.11.001) PMID: [26628378](https://pubmed.ncbi.nlm.nih.gov/26628378/).
 27. Magno RC, Lemgruber L, Vommaro RC, De Souza W, Attias M. Intravacuolar network may act as a mechanical support for *Toxoplasma gondii* inside the parasitophorous vacuole. *Microscopy research and technique*. 2005; 67(1):45–52. Epub 2005/07/19. doi: [10.1002/jemt.20182](https://doi.org/10.1002/jemt.20182) PMID: [16025490](https://pubmed.ncbi.nlm.nih.gov/16025490/).
 28. Sibley LD, Krahenbuhl JL, Adams GM, Weidner E. *Toxoplasma* modifies macrophage phagosomes by secretion of a vesicular network rich in surface proteins. *The Journal of cell biology*. 1986; 103(3):867–74. Epub 1986/09/01. PMID: [3528173](https://pubmed.ncbi.nlm.nih.gov/3528173/); PubMed Central PMCID: PMC2114290.
 29. Coppens I, Dunn JD, Romano JD, Pypaert M, Zhang H, Boothroyd JC, et al. *Toxoplasma gondii* sequesters lysosomes from mammalian hosts in the vacuolar space. *Cell*. 2006; 125(2):261–74. PMID: [16630815](https://pubmed.ncbi.nlm.nih.gov/16630815/).
 30. Dunn JD, Ravindran S, Kim SK, Boothroyd JC. The *Toxoplasma gondii* dense granule protein GRA7 is phosphorylated upon invasion and forms an unexpected association with the rho-try proteins ROP2 and ROP4. *Infection and immunity*. 2008; 76(12):5853–61. Epub 2008/09/24. doi: [10.1128/IAI.01667-07](https://doi.org/10.1128/IAI.01667-07) PMID: [18809661](https://pubmed.ncbi.nlm.nih.gov/18809661/); PubMed Central PMCID: PMC2583583.
 31. Alaganaan A, Fentress SJ, Tang K, Wang Q, Sibley LD. *Toxoplasma* GRA7 effector increases turnover of immunity-related GTPases and contributes to acute virulence in the mouse. *Proceedings of the National Academy of Sciences of the United States of America*. 2014; 111(3):1126–31. Epub 2014/01/07. doi: [10.1073/pnas.1313501111](https://doi.org/10.1073/pnas.1313501111) PMID: [24390541](https://pubmed.ncbi.nlm.nih.gov/24390541/); PubMed Central PMCID: PMC3903209.
 32. Fentress SJ, Behnke MS, Dunay IR, Mashayekhi M, Rommereim LM, Fox BA, et al. Phosphorylation of immunity-related GTPases by a *Toxoplasma gondii*-secreted kinase promotes macrophage survival and virulence. *Cell Host Microbe*. 2010; 8(6):484–95. Epub 2010/12/15. doi: [10.1016/j.chom.2010.11.005](https://doi.org/10.1016/j.chom.2010.11.005) PMID: [21147463](https://pubmed.ncbi.nlm.nih.gov/21147463/); PubMed Central PMCID: PMC3013631.
 33. Okada T, Marmansari D, Li ZM, Adilbish A, Canko S, Ueno A, et al. A novel dense granule protein, GRA22, is involved in regulating parasite egress in *Toxoplasma gondii*. *Molecular and biochemical parasitology*. 2013; 189(1–2):5–13. Epub 2013/04/30. doi: [10.1016/j.molbiopara.2013.04.005](https://doi.org/10.1016/j.molbiopara.2013.04.005) PMID: [23623919](https://pubmed.ncbi.nlm.nih.gov/23623919/).
 34. Gold DA, Kaplan AD, Lis A, Bett GC, Rosowski EE, Cirelli KM, et al. The *Toxoplasma* Dense Granule Proteins GRA17 and GRA23 Mediate the Movement of Small Molecules between the Host and the Parasitophorous Vacuole. *Cell host & microbe*. 2015; 17(5):642–52. Epub 2015/05/15. doi: [10.1016/j.chom.2015.04.003](https://doi.org/10.1016/j.chom.2015.04.003) PMID: [25974303](https://pubmed.ncbi.nlm.nih.gov/25974303/); PubMed Central PMCID: PMC4435723.
 35. Ma JS, Sasai M, Ohshima J, Lee Y, Bando H, Takeda K, et al. Selective and strain-specific NFAT4 activation by the *Toxoplasma gondii* polymorphic dense granule protein GRA6. *The Journal of experimental medicine*. 2014; 211(10):2013–32. Epub 2014/09/17. doi: [10.1084/jem.20131272](https://doi.org/10.1084/jem.20131272) PMID: [25225460](https://pubmed.ncbi.nlm.nih.gov/25225460/); PubMed Central PMCID: PMC4172224.
 36. Persat F, Mercier C, Ficheux D, Colomb E, Trouillet S, Bendridi N, et al. A synthetic peptide derived from the parasite *Toxoplasma gondii* triggers human dendritic cells' migration. *Journal of leukocyte biology*. 2012; 92(6):1241–50. Epub 2012/10/04. doi: [10.1189/jlb.1211600](https://doi.org/10.1189/jlb.1211600) PMID: [23033174](https://pubmed.ncbi.nlm.nih.gov/23033174/).
 37. Shastri AJ, Marino ND, Franco M, Lodoen MB, Boothroyd JC. GRA25 is a novel virulence factor of *Toxoplasma gondii* and influences the host immune response. *Infection and immunity*. 2014; 82(6):2595–605. Epub 2014/04/09. doi: [10.1128/IAI.01339-13](https://doi.org/10.1128/IAI.01339-13) PMID: [24711568](https://pubmed.ncbi.nlm.nih.gov/24711568/); PubMed Central PMCID: PMC4019154.
 38. Bougdour A, Tardieux I, Hakimi MA. *Toxoplasma* exports dense granule proteins beyond the vacuole to the host cell nucleus and rewires the host genome expression. *Cellular microbiology*. 2014; 16(3):334–43. Epub 2014/01/01. doi: [10.1111/cmi.12255](https://doi.org/10.1111/cmi.12255) PMID: [24373221](https://pubmed.ncbi.nlm.nih.gov/24373221/).
 39. Rosowski EE, Lu D, Julien L, Rodda L, Gaiser RA, Jensen KD, et al. Strain-specific activation of the NF-kappaB pathway by GRA15, a novel *Toxoplasma gondii* dense granule protein. *J Exp Med*. 2011; 208(1):195–212. Epub 2011/01/05. doi: [10.1084/jem.20100717](https://doi.org/10.1084/jem.20100717) PMID: [21199955](https://pubmed.ncbi.nlm.nih.gov/21199955/); PubMed Central PMCID: PMC3023140.
 40. Bougdour A, Durandau E, Brenier-Pinchart MP, Ortet P, Barakat M, Kieffer S, et al. Host Cell Subversion by *Toxoplasma* GRA16, an Exported Dense Granule Protein that Targets the Host Cell Nucleus and Alters Gene Expression. *Cell Host Microbe*. 2013; 13(4):489–500. Epub 2013/04/23. doi: [10.1016/j.chom.2013.03.002](https://doi.org/10.1016/j.chom.2013.03.002) PMID: [23601110](https://pubmed.ncbi.nlm.nih.gov/23601110/).

41. Braun L, Brenier-Pinchart MP, Yogavel M, Curt-Varesano A, Curt-Bertini RL, Hussain T, et al. A *Toxoplasma* dense granule protein, GRA24, modulates the early immune response to infection by promoting a direct and sustained host p38 MAPK activation. *The Journal of experimental medicine*. 2013; 210(10):2071–86. Epub 2013/09/18. doi: [10.1084/jem.20130103](https://doi.org/10.1084/jem.20130103) PMID: [24043761](https://pubmed.ncbi.nlm.nih.gov/24043761/); PubMed Central PMCID: [PMC3782045](https://pubmed.ncbi.nlm.nih.gov/PMC3782045/).
42. Mercier C, Howe DK, Mordue D, Lingnau M, Sibley LD. Targeted disruption of the GRA2 locus in *Toxoplasma gondii* decreases acute virulence in mice. *Infect Immun*. 1998; 66(9):4176–82. PMID: [9712765](https://pubmed.ncbi.nlm.nih.gov/9712765/).
43. Mercier C, Rauscher B, Lecordier L, Deslee D, Dubremetz JF, Cesbron-Delauw MF. Lack of expression of the dense granule protein GRA5 does not affect the development of *Toxoplasma* tachyzoites. *Molecular and biochemical parasitology*. 2001; 116(2):247–51. Epub 2001/08/28. PMID: [11522359](https://pubmed.ncbi.nlm.nih.gov/11522359/).
44. Rome ME, Beck JR, Turetzky JM, Webster P, Bradley PJ. Intervacuolar transport and unique topology of GRA14, a novel dense granule protein in *Toxoplasma gondii*. *Infection and immunity*. 2008; 76(11):4865–75. Epub 2008/09/04. doi: [10.1128/IAI.00782-08](https://doi.org/10.1128/IAI.00782-08) PMID: [18765740](https://pubmed.ncbi.nlm.nih.gov/18765740/); PubMed Central PMCID: [PMC2573327](https://pubmed.ncbi.nlm.nih.gov/PMC2573327/).
45. Craver MP, Knoll LJ. Increased efficiency of homologous recombination in *Toxoplasma gondii* dense granule protein 3 demonstrates that GRA3 is not necessary in cell culture but does contribute to virulence. *Molecular and biochemical parasitology*. 2007; 153(2):149–57. Epub 2007/04/10. doi: [10.1016/j.molbiopara.2007.02.013](https://doi.org/10.1016/j.molbiopara.2007.02.013) PMID: [17418907](https://pubmed.ncbi.nlm.nih.gov/17418907/).
46. Fox BA, Falla A, Rommereim LM, Tomita T, Gigley JP, Mercier C, et al. Type II *Toxoplasma gondii* KU80 knockout strains enable functional analysis of genes required for cyst development and latent infection. *Eukaryot Cell*. 2011; 10(9):1193–206. Epub 2011/05/03. doi: [10.1128/EC.00297-10](https://doi.org/10.1128/EC.00297-10) PMID: [21531875](https://pubmed.ncbi.nlm.nih.gov/21531875/); PubMed Central PMCID: [PMC3187049](https://pubmed.ncbi.nlm.nih.gov/PMC3187049/).
47. Rommereim LM, Hortua Triana MA, Falla A, Sanders KL, Guevara RB, Bzik DJ, et al. Genetic manipulation in Deltaku80 strains for functional genomic analysis of *Toxoplasma gondii*. *J Vis Exp*. 2013;(77): e50598. Epub 2013/07/31. doi: [10.3791/50598](https://doi.org/10.3791/50598) PMID: [23892917](https://pubmed.ncbi.nlm.nih.gov/23892917/); PubMed Central PMCID: [PMC3735270](https://pubmed.ncbi.nlm.nih.gov/PMC3735270/).
48. Fox BA, Ristuccia JG, Gigley JP, Bzik DJ. Efficient gene replacements in *Toxoplasma gondii* strains deficient for nonhomologous end joining. *Eukaryot Cell*. 2009; 8(4):520–9. PMID: [19218423](https://pubmed.ncbi.nlm.nih.gov/19218423/) doi: [10.1128/EC.00357-08](https://doi.org/10.1128/EC.00357-08)
49. Huynh MH, Carruthers VB. Tagging of endogenous genes in a *Toxoplasma gondii* strain lacking Ku80. *Eukaryot Cell*. 2009; 8(4):530–9. PMID: [19218426](https://pubmed.ncbi.nlm.nih.gov/19218426/) doi: [10.1128/EC.00358-08](https://doi.org/10.1128/EC.00358-08)
50. Gajria B, Bahl A, Brestelli J, Dommer J, Fischer S, Gao X, et al. ToxoDB: an integrated *Toxoplasma gondii* database resource. *Nucleic Acids Res*. 2008; 36(Database issue):D553–6. PMID: [18003657](https://pubmed.ncbi.nlm.nih.gov/18003657/).
51. Gigley JP, Fox BA, Bzik DJ. Cell-mediated immunity to *Toxoplasma gondii* develops primarily by local Th1 host immune responses in the absence of parasite replication. *J Immunol*. 2009; 182(2):1069–78. PMID: [19124750](https://pubmed.ncbi.nlm.nih.gov/19124750/).
52. Achbarou A, Mercereau-Puijalon O, Sadak A, Fortier B, Leriche MA, Camus D, et al. Differential targeting of dense granule proteins in the parasitophorous vacuole of *Toxoplasma gondii*. *Parasitology*. 1991; 103 Pt 3:321–9. PMID: [1780169](https://pubmed.ncbi.nlm.nih.gov/1780169/).
53. Labruyere E, Lingnau M, Mercier C, Sibley LD. Differential membrane targeting of the secretory proteins GRA4 and GRA6 within the parasitophorous vacuole formed by *Toxoplasma gondii*. *Mol Biochem Parasitol*. 1999; 102(2):311–24. PMID: [10498186](https://pubmed.ncbi.nlm.nih.gov/10498186/).
54. Saavedra R, De Meuter F, Herion P. Monoclonal antibodies identify new *Toxoplasma gondii* soluble antigens. *Hybridoma*. 1990; 9(5):453–63. PMID: [2258184](https://pubmed.ncbi.nlm.nih.gov/2258184/).
55. Carey KL, Donahue CG, Ward GE. Identification and molecular characterization of GRA8, a novel, proline-rich, dense granule protein of *Toxoplasma gondii*. *Molecular and biochemical parasitology*. 2000; 105(1):25–37. PMID: [10613696](https://pubmed.ncbi.nlm.nih.gov/10613696/).
56. Adjogble KD, Mercier C, Dubremetz JF, Hucke C, Mackenzie CR, Cesbron-Delauw MF, et al. GRA9, a new *Toxoplasma gondii* dense granule protein associated with the intravacuolar network of tubular membranes. *International journal for parasitology*. 2004; 34(11):1255–64. doi: [10.1016/j.ijpara.2004.07.011](https://doi.org/10.1016/j.ijpara.2004.07.011) PMID: [15491588](https://pubmed.ncbi.nlm.nih.gov/15491588/).
57. Dobrowolski JM, Sibley LD. *Toxoplasma* invasion of mammalian cells is powered by the actin cytoskeleton of the parasite. *Cell*. 1996; 84(6):933–9. PMID: [8601316](https://pubmed.ncbi.nlm.nih.gov/8601316/).
58. Rodriguez C, Afchain D, Capron A, Dissous C, Santoro F. Major surface protein of *Toxoplasma gondii* (p30) contains an immunodominant region with repetitive epitopes. *European journal of immunology*. 1985; 15(7):747–9. doi: [10.1002/eji.1830150721](https://doi.org/10.1002/eji.1830150721) PMID: [2408905](https://pubmed.ncbi.nlm.nih.gov/2408905/).
59. Donald RG, Carter D, Ullman B, Roos DS. Insertional tagging, cloning, and expression of the *Toxoplasma gondii* hypoxanthine-xanthine-guanine phosphoribosyltransferase gene. Use as a selectable marker for stable transformation. *J Biol Chem*. 1996; 271(24):14010–9. PMID: [8662859](https://pubmed.ncbi.nlm.nih.gov/8662859/).

60. Cesbron-Delauw MF, Gendrin C, Travier L, Ruffiot P, Mercier C. Apicomplexa in mammalian cells: trafficking to the parasitophorous vacuole. *Traffic*. 2008; 9(5):657–64. Epub 2008/03/05. doi: [10.1111/j.1600-0854.2008.00728.x](https://doi.org/10.1111/j.1600-0854.2008.00728.x) PMID: [18315533](https://pubmed.ncbi.nlm.nih.gov/18315533/).
61. Braun L, Travier L, Kieffer S, Musset K, Garin J, Mercier C, et al. Purification of *Toxoplasma* dense granule proteins reveals that they are in complexes throughout the secretory pathway. *Mol Biochem Parasitol*. 2008; 157(1):13–21. PMID: [17959262](https://pubmed.ncbi.nlm.nih.gov/17959262/).
62. Witola WH, Bauman B, McHugh M, Matthews K. Silencing of GRA10 protein expression inhibits *Toxoplasma gondii* intracellular growth and development. *Parasitology international*. 2014; 63(5):651–8. Epub 2014/05/17. doi: [10.1016/j.parint.2014.05.001](https://doi.org/10.1016/j.parint.2014.05.001) PMID: [24832208](https://pubmed.ncbi.nlm.nih.gov/24832208/).
63. Cesbron-Delauw MF, Guy B, Torpier G, Pierce RJ, Lenzen G, Cesbron JY, et al. Molecular characterization of a 23-kilodalton major antigen secreted by *Toxoplasma gondii*. *Proceedings of the National Academy of Sciences of the United States of America*. 1989; 86(19):7537–41. Epub 1989/10/01. PMID: [2798425](https://pubmed.ncbi.nlm.nih.gov/2798425/); PubMed Central PMCID: PMC298100.
64. Andenmatten N, Egarter S, Jackson AJ, Jullien N, Herman JP, Meissner M. Conditional genome engineering in *Toxoplasma gondii* uncovers alternative invasion mechanisms. *Nature methods*. 2013; 10(2):125–7. Epub 2012/12/25. doi: [10.1038/nmeth.2301](https://doi.org/10.1038/nmeth.2301) PMID: [23263690](https://pubmed.ncbi.nlm.nih.gov/23263690/); PubMed Central PMCID: PMC3605914.
65. Limenitakis J, Soldati-Favre D. Functional genetics in Apicomplexa: potentials and limits. *FEBS letters*. 2011; 585(11):1579–88. Epub 2011/05/12. doi: [10.1016/j.febslet.2011.05.002](https://doi.org/10.1016/j.febslet.2011.05.002) PMID: [21557944](https://pubmed.ncbi.nlm.nih.gov/21557944/).
66. Shen B, Brown KM, Lee TD, Sibley LD. Efficient gene disruption in diverse strains of *Toxoplasma gondii* using CRISPR/CAS9. *mBio*. 2014; 5(3):e01114–14. Epub 2014/05/16. doi: [10.1128/mBio.01114-14](https://doi.org/10.1128/mBio.01114-14) PMID: [24825012](https://pubmed.ncbi.nlm.nih.gov/24825012/); PubMed Central PMCID: PMC4030483.
67. Mercier C, Travier L, Bittame A, Gendrin C, Cesbron-Delauw MF. The Dense Granule Proteins of *Toxoplasma gondii*. In: De Bruyn O, Peeters S, editors. *Parasitology Research Trends*: Nova Science Publishers; 2010.
68. Mercier C, Cesbron-Delauw MF. *Toxoplasma* secretory granules: one population or more? *Trends in parasitology*. 2015; 31(2):60–71. Epub 2015/01/21. doi: [10.1016/j.pt.2014.12.002](https://doi.org/10.1016/j.pt.2014.12.002) PMID: [25599584](https://pubmed.ncbi.nlm.nih.gov/25599584/).
69. Dou Z, McGovern OL, Di Cristina M, Carruthers VB. *Toxoplasma gondii* ingests and digests host cytosolic proteins. *mBio*. 2014; 5(4):e01188–14. Epub 2014/07/17. doi: [10.1128/mBio.01188-14](https://doi.org/10.1128/mBio.01188-14) PMID: [25028423](https://pubmed.ncbi.nlm.nih.gov/25028423/); PubMed Central PMCID: PMC4161261.
70. Mercier C, Cesbron-Delauw MF, Ferguson DJ. Dense granules of the infectious stages of *Toxoplasma gondii*: Their central role in the host/parasite relationship. In: Soldati D, Ajioka JW, editors. *Toxoplasma: Molecular and Cellular Biology*. Norfolk, UK: Horizon Bioscience; 2007. p. 475–92.
71. Ferguson DJ, Cesbron-Delauw MF, Dubremetz JF, Sibley LD, Joiner KA, Wright S. The expression and distribution of dense granule proteins in the enteric (Coccidian) forms of *Toxoplasma gondii* in the small intestine of the cat. *Experimental parasitology*. 1999; 91(3):203–11. Epub 1999/03/11. doi: [10.1006/expr.1998.4384](https://doi.org/10.1006/expr.1998.4384) PMID: [10072322](https://pubmed.ncbi.nlm.nih.gov/10072322/).
72. Torpier G, Charif H, Darcy F, Liu J, Darde ML, Capron A. *Toxoplasma gondii*: differential location of antigens secreted from encysted bradyzoites. *Exp Parasitol*. 1993; 77(1):13–22. PMID: [8344403](https://pubmed.ncbi.nlm.nih.gov/8344403/).
73. Ferguson DJ. Use of molecular and ultrastructural markers to evaluate stage conversion of *Toxoplasma gondii* in both the intermediate and definitive host. *Int J Parasitol*. 2004; 34(3):347–60. PMID: [15003495](https://pubmed.ncbi.nlm.nih.gov/15003495/).
74. Lemgruber L, Lupetti P, Martins-Duarte ES, De Souza W, Vommaro RC. The organization of the wall filaments and characterization of the matrix structures of *Toxoplasma gondii* cyst form. *Cellular microbiology*. 2011; 13(12):1920–32. Epub 2011/09/09. doi: [10.1111/j.1462-5822.2011.01681.x](https://doi.org/10.1111/j.1462-5822.2011.01681.x) PMID: [21899696](https://pubmed.ncbi.nlm.nih.gov/21899696/).